No Data
No Data
No Data
No Data
No Data
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will
GlobeNewswireApr 18 07:00 ET
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Seeking AlphaMar 10 13:08 ET
Correction to SpringWorks Therapeutics Rating on March 6
JP Morgan raised its price target on SpringWorks to $75.00/share from $74.00/share. "SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by JP Morgan" at 6:49 a.m. ET on March 6 i
Dow JonesMar 8 11:04 ET
SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by HC Wainwright & Co.
SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by HC Wainwright & Co.
Dow JonesMar 6 08:37 ET
SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan
SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan
Dow JonesMar 6 06:49 ET
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
TipRanksMar 6 06:40 ET
No Data
No Data